MiMedx Group, Inc. Announces Merger Agreement to Acquire Sanara MedTech

What Happened
MiMedx Group, Inc. (MiMedx) announced on July 29, 2026 that it entered into a definitive Agreement and Plan of Merger to combine with Sanara MedTech, Inc. Under the deal, Merger Subsidiary will merge into Sanara with Sanara surviving as a MiMedx subsidiary. Each outstanding share of Sanara common stock (other than excluded shares) will be converted into $33.00 in cash plus 0.4735 shares of MiMedx common stock (the stock portion was valued at $2.00 per Sanara share based on MiMedx’s five‑day average through July 29, 2026). The MiMedx shares to be issued will be registered on Form S‑4 and listed on Nasdaq.

Key Details

• Deal date: Merger Agreement executed July 29, 2026; outside “End Date” to close is July 29, 2027 (can be extended to Jan 29, 2028 for antitrust delays).
• Consideration: $33.00 cash + 0.4735 MiMedx shares per Sanara share (stock portion valued at $2.00/share for pricing).
• Financing: MiMedx obtained a debt commitment letter for a $300.0 million first‑lien senior secured term loan facility from funds managed/advised by Hayfin Capital Management LLP (subject to customary conditions). Existing credit agreement will be repaid upon financing.
• Stockholder support & voting: Specified Sanara stockholders holding ~38.9% of voting power signed a voting agreement to vote in favor of the merger.
• Employee equity treatment: Sanara restricted stock converts to cash + MiMedx shares; Sanara options convert to a cash payment equal to the merger value minus exercise price.
• Break fees: Sanara would owe MiMedx a termination fee of $22,540,785 in certain circumstances; MiMedx would owe Sanara $9,660,336 if MiMedx fails to close when required.

Why It Matters
For investors, this is a strategic acquisition that will add Sanara as a MiMedx subsidiary and will be funded in part by $300M of committed debt. The deal involves both cash and stock consideration, which will dilute existing MiMedx shareholders to the extent new shares are issued. Key risks to completing the transaction include Sanara stockholder approval, antitrust/HSR clearance, successful registration of MiMedx shares on Form S‑4, and the absence of a material adverse change at Sanara. The filing also discloses significant termination fees and a voting agreement covering nearly 39% of Sanara’s votes, which may increase the likelihood of closing if other conditions are met.